Objective: To observe the clinical efficacy and differences of the Zhuyu Juanbi formula delivered through ultrasound at Zusanli on patients with chemotherapy-induced peripheral neuropathy (CIPN) due to paclitaxel inje...Objective: To observe the clinical efficacy and differences of the Zhuyu Juanbi formula delivered through ultrasound at Zusanli on patients with chemotherapy-induced peripheral neuropathy (CIPN) due to paclitaxel injection. Methods: A total of 72 breast cancer patients with CIPN were randomly divided into two groups. The treatment group (36 cases) was treated with oral methylcobalamin plus ultrasonic medicine permeating Zhuyu Juanbi formulae, while the control group (36 cases) was treated with oral methylcobalamin alone. Following two 2 cycles of continuous treatment, the efficacy of peripheral neurotoxicity, TCM syndrome score, FACT/GOG-Ntx score, total neuropathy score, and safety indicators of gynecological cancer patients were observed in the two groups. Result: In the treatment of CIPN, the addition of ultrasonic medicine permeating Zhuyu Juanbi formulae was more effective than oral methylcobalamin alone in reducing peripheral neurotoxicity and improving the quality of life of patients. The difference between the two groups was statistically significant (P < 0.05), and ultrasound drug penetration Zhuyu Juanbi formulae significantly reduced the FACT/ GOG-Ntx score and TNS score in the treatment group. In terms of drug safety, it rarely caused adverse reactions such as grade 3 and 4 leukopenia, and the safety profile was therefore good. Conclusion: The combination of ultrasonic medicine permeating Zhuyu Juanbi formulae and methylcobalamin has been demonstrated to be an effective treatment for peripheral neurotoxicity in patients with PIPN. It has been shown to significantly improve the clinical symptoms of PIPN patients, improve the quality of life of patients, and have a good safety profile.展开更多
[Objectives]To observe the clinical efficacy and safety of Zhuang Medicine Xiaoyan Zhiyang Formula by retrospective analysis of clinical use.[Methods]A total of 225 cases were collected,including 117 males and 108 fem...[Objectives]To observe the clinical efficacy and safety of Zhuang Medicine Xiaoyan Zhiyang Formula by retrospective analysis of clinical use.[Methods]A total of 225 cases were collected,including 117 males and 108 females,115 cases of contact dermatitis and 110 cases of acute eczema.Zhuang Medicine Xiaoyan Zhiyang Formula was administered to 225 patients with contact dermatitis and acute eczema and the clinical efficacy was evaluated.[Results]After one week of treatment,among 225 patients with contact dermatitis and acute eczema,76 cases were cured(33.78%),133 cases showed marked response(59.11%),16 cases(7.11%)were improved,0 case was ineffective,and the overall response rate was 92.89%.After one week of Zhuang Medicine Xiaoyan Zhiyang Formula treatment,the symptoms of itching,pain and swelling were significantly improved in all patients,and the rash was partially crusted without new symptom,and there were no complications and adverse reactions.[Conclusions]Zhuang Medicine Xiaoyan Zhiyang Formula therapy has a remarkable effect in the treatment of contact dermatitis and acute eczema.展开更多
Objective To explore the rules and characteristics of the adverse drug reactions(ADRs)of three Chinese patent medicines and three herbal formulas for the treatment of COVID-19,and to provide a reference for clinical s...Objective To explore the rules and characteristics of the adverse drug reactions(ADRs)of three Chinese patent medicines and three herbal formulas for the treatment of COVID-19,and to provide a reference for clinical safe medication.Methods The cases and ADR reports of the three Chinese patent medicines and three herbal formulas in PubMed,Web of Science,Springer Link,CNKI,Wanfang and VIP database were retrieved from December 2019 to May 2021.Then we extracted and analyzed the effective information included in the literature.Results and Conclusion According to the pre-developed retrieval plan,a total of 136 documents were obtained,and a total of 6 documents met the inclusion criteria finally.553 patients used three Chinese patent medicines and three herbal formulas,and there were 133 cases of adverse reactions.The adverse reactions of patients taking the three Chinese patent medicines and three herbal formulas can all be explained under the theory of traditional Chinese medicine,and the adverse reactions can be eliminated by adding or subtracting the flavor of the medicine or stopping the medicine.展开更多
Objective:Parkinson’s disease(PD)is the second largest neurodegenerative disease following Alzheimer’s disease(AD),which associated with aging.There are many similarities in pathology and pathogenesis,even in the TC...Objective:Parkinson’s disease(PD)is the second largest neurodegenerative disease following Alzheimer’s disease(AD),which associated with aging.There are many similarities in pathology and pathogenesis,even in the TCM theory understanding,so we can learn from each other in the process of drug discovery.The clinical results showed that Bushen-Yizhi formula(BSYZ)could effectively improve the neurological function score of senile dementia patients and had a better anti-dementia effect.Further pharmacological studies showed that BSYZ had neuroprotective effects,such as anti-inflammatory,anti-oxidation,anti-apoptosis and neurotrophic effects.In this study,the therapeutic effect of BSYZ on PD was evaluated in vivo and in vivo,and its molecular mechanism was discussed in order to expand the scope of application of BSYZ and to provide strategies for drug discovery of related neurodegenerative diseases.Methods:C57 BL/6 mice were injected intraperitoneally with MPTP to construct a PD mouse model.BSYZ(1.46,2.92,5.84 mg·kg-1)was administered for two weeks,and the positive control group was given a NSAID,piroxicam(12.5 mg·kg-1).After 1 week of pretreatment,MPTP was used to construct a PD mouse model.The mice were subjected to Rotation test on days 1,3 and 5,6th day.and the movement coordination and exercise ability of the drug on PD mice were observed on theThe number of TH-positive cells,Iba1 and CD68-labeled microglial cells in SNpc region were observed by immunofluorescence to observe the proliferation and activation of microglial cells and GFAP-labeled astrocytes.Western blotting was used to detect the nuclear transfer of NLRP3,Caspase-1,ASC,pro-IL-1β,IL-1βand NF-κB in the midbrain.Results:1.BSYZ could significantly improve the expression of MPTP model mice in the experiment of fatigue and Y-maze,increase the number of neurons in SNpc region and the positive expression of TH protein.2.BSYZ significantly inhibited the number of Iba1/CD68-positive microglial cells in MPTP-model mice and decreased the number of GFAP-positive astrocytes.3.BSYZ significantly inhibited the expression of NLRP3-associated protein in BV2 microglial cells induced by LPS+ATP and inhibited the nuclear transfer of NF-κB.Conclusion:BSYZ can effectively relieve the motor dysfunction of PD model mice,improve the damage of dopaminergic neurons,inhibit the proliferation and activation of microglial cells and astrocytes,and have good anti-MPTPinduced neuroinflammation and neuroinflammation mediated by nuclear transfer of NF-κB.The results show that BSYZ has a good prospect of anti-Parkinson’s disease and provides valuable drug discovery strategies for the related neurodegenerative diseases.展开更多
文摘Objective: To observe the clinical efficacy and differences of the Zhuyu Juanbi formula delivered through ultrasound at Zusanli on patients with chemotherapy-induced peripheral neuropathy (CIPN) due to paclitaxel injection. Methods: A total of 72 breast cancer patients with CIPN were randomly divided into two groups. The treatment group (36 cases) was treated with oral methylcobalamin plus ultrasonic medicine permeating Zhuyu Juanbi formulae, while the control group (36 cases) was treated with oral methylcobalamin alone. Following two 2 cycles of continuous treatment, the efficacy of peripheral neurotoxicity, TCM syndrome score, FACT/GOG-Ntx score, total neuropathy score, and safety indicators of gynecological cancer patients were observed in the two groups. Result: In the treatment of CIPN, the addition of ultrasonic medicine permeating Zhuyu Juanbi formulae was more effective than oral methylcobalamin alone in reducing peripheral neurotoxicity and improving the quality of life of patients. The difference between the two groups was statistically significant (P < 0.05), and ultrasound drug penetration Zhuyu Juanbi formulae significantly reduced the FACT/ GOG-Ntx score and TNS score in the treatment group. In terms of drug safety, it rarely caused adverse reactions such as grade 3 and 4 leukopenia, and the safety profile was therefore good. Conclusion: The combination of ultrasonic medicine permeating Zhuyu Juanbi formulae and methylcobalamin has been demonstrated to be an effective treatment for peripheral neurotoxicity in patients with PIPN. It has been shown to significantly improve the clinical symptoms of PIPN patients, improve the quality of life of patients, and have a good safety profile.
基金Supported by Scientific Research Project of Guangxi Zhuang Autonomous Region Food and Drug Administration(2021 Guangxi Drug Safety Scientific Research Project)"Safety Evaluation of Zhuang Medicine Xiaoyan Zhiyang Formula for the Treatment of Acute Eczema and Contact Dermatitis and Other Skin Diseases"State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project of Traditional Chinese Medicine-Ethnic Minority Pharmacy(Zhuang Pharmacy)(zyyzdxk-2023165)+2 种基金Guangxi Traditional Chinese Medicine Multidisciplinary Innovation Team Project(GZKJ2309)Funding Project of High-level Talent Cultivation and Innovation Team of Guangxi University of Traditional Chinese Medicine(2022A008)Key R&D Projects of Guangxi Science and Technology Department(Gui Ke AB21196057).
文摘[Objectives]To observe the clinical efficacy and safety of Zhuang Medicine Xiaoyan Zhiyang Formula by retrospective analysis of clinical use.[Methods]A total of 225 cases were collected,including 117 males and 108 females,115 cases of contact dermatitis and 110 cases of acute eczema.Zhuang Medicine Xiaoyan Zhiyang Formula was administered to 225 patients with contact dermatitis and acute eczema and the clinical efficacy was evaluated.[Results]After one week of treatment,among 225 patients with contact dermatitis and acute eczema,76 cases were cured(33.78%),133 cases showed marked response(59.11%),16 cases(7.11%)were improved,0 case was ineffective,and the overall response rate was 92.89%.After one week of Zhuang Medicine Xiaoyan Zhiyang Formula treatment,the symptoms of itching,pain and swelling were significantly improved in all patients,and the rash was partially crusted without new symptom,and there were no complications and adverse reactions.[Conclusions]Zhuang Medicine Xiaoyan Zhiyang Formula therapy has a remarkable effect in the treatment of contact dermatitis and acute eczema.
文摘Objective To explore the rules and characteristics of the adverse drug reactions(ADRs)of three Chinese patent medicines and three herbal formulas for the treatment of COVID-19,and to provide a reference for clinical safe medication.Methods The cases and ADR reports of the three Chinese patent medicines and three herbal formulas in PubMed,Web of Science,Springer Link,CNKI,Wanfang and VIP database were retrieved from December 2019 to May 2021.Then we extracted and analyzed the effective information included in the literature.Results and Conclusion According to the pre-developed retrieval plan,a total of 136 documents were obtained,and a total of 6 documents met the inclusion criteria finally.553 patients used three Chinese patent medicines and three herbal formulas,and there were 133 cases of adverse reactions.The adverse reactions of patients taking the three Chinese patent medicines and three herbal formulas can all be explained under the theory of traditional Chinese medicine,and the adverse reactions can be eliminated by adding or subtracting the flavor of the medicine or stopping the medicine.
文摘Objective:Parkinson’s disease(PD)is the second largest neurodegenerative disease following Alzheimer’s disease(AD),which associated with aging.There are many similarities in pathology and pathogenesis,even in the TCM theory understanding,so we can learn from each other in the process of drug discovery.The clinical results showed that Bushen-Yizhi formula(BSYZ)could effectively improve the neurological function score of senile dementia patients and had a better anti-dementia effect.Further pharmacological studies showed that BSYZ had neuroprotective effects,such as anti-inflammatory,anti-oxidation,anti-apoptosis and neurotrophic effects.In this study,the therapeutic effect of BSYZ on PD was evaluated in vivo and in vivo,and its molecular mechanism was discussed in order to expand the scope of application of BSYZ and to provide strategies for drug discovery of related neurodegenerative diseases.Methods:C57 BL/6 mice were injected intraperitoneally with MPTP to construct a PD mouse model.BSYZ(1.46,2.92,5.84 mg·kg-1)was administered for two weeks,and the positive control group was given a NSAID,piroxicam(12.5 mg·kg-1).After 1 week of pretreatment,MPTP was used to construct a PD mouse model.The mice were subjected to Rotation test on days 1,3 and 5,6th day.and the movement coordination and exercise ability of the drug on PD mice were observed on theThe number of TH-positive cells,Iba1 and CD68-labeled microglial cells in SNpc region were observed by immunofluorescence to observe the proliferation and activation of microglial cells and GFAP-labeled astrocytes.Western blotting was used to detect the nuclear transfer of NLRP3,Caspase-1,ASC,pro-IL-1β,IL-1βand NF-κB in the midbrain.Results:1.BSYZ could significantly improve the expression of MPTP model mice in the experiment of fatigue and Y-maze,increase the number of neurons in SNpc region and the positive expression of TH protein.2.BSYZ significantly inhibited the number of Iba1/CD68-positive microglial cells in MPTP-model mice and decreased the number of GFAP-positive astrocytes.3.BSYZ significantly inhibited the expression of NLRP3-associated protein in BV2 microglial cells induced by LPS+ATP and inhibited the nuclear transfer of NF-κB.Conclusion:BSYZ can effectively relieve the motor dysfunction of PD model mice,improve the damage of dopaminergic neurons,inhibit the proliferation and activation of microglial cells and astrocytes,and have good anti-MPTPinduced neuroinflammation and neuroinflammation mediated by nuclear transfer of NF-κB.The results show that BSYZ has a good prospect of anti-Parkinson’s disease and provides valuable drug discovery strategies for the related neurodegenerative diseases.
